67 related articles for article (PubMed ID: 19969344)
21. 2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis.
Geier SA; Klauss V; Matuschke A; Kronawitter U; Goebel FD
Ger J Ophthalmol; 1992; 1(2):110-3. PubMed ID: 1335812
[TBL] [Abstract][Full Text] [Related]
22. Preparation and Evaluation of Biodegradable Scleral Plug Containing Curcumin in Rabbit Eye.
Zhang J; Sun H; Zhou N; Zhang B; Ma J
Curr Eye Res; 2017 Dec; 42(12):1597-1603. PubMed ID: 29111828
[TBL] [Abstract][Full Text] [Related]
23. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis.
Arevalo JF; Gonzalez C; Capparelli EV; Kirsch LS; Garcia RF; Quiceno JI; Connor JD; Gambertoglio J; Bergeron-Lynn G; Freeman WR
J Infect Dis; 1995 Oct; 172(4):951-6. PubMed ID: 7561215
[TBL] [Abstract][Full Text] [Related]
24. New developments in the delivery of ganciclovir for cytomegalovirus (CMV retinitis).
Woodward J
STEP Perspect; 1995; 7(2):2-4. PubMed ID: 11362720
[TBL] [Abstract][Full Text] [Related]
25. Re-evaluation of time to progression of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients clinically resistant to ganciclovir.
Mueller AJ; Jacobson MA; Hurwitz S; Chuang EL; Friedberg DN; Haidt SJ; Heinemann MH; Jabs DA; Kaplan HJ; Freeman WR
AIDS; 1997 Mar; 11(3):397-9. PubMed ID: 9147441
[No Abstract] [Full Text] [Related]
26. The progressive outer retinal necrosis syndrome: successful treatment with combination antiviral therapy.
Ciulla TA; Rutledge BK; Morley MG; Duker JS
Ophthalmic Surg Lasers; 1998 Mar; 29(3):198-206. PubMed ID: 9547773
[TBL] [Abstract][Full Text] [Related]
27. New treatment options for CMV retinitis in AIDS.
Lalezari JP
Adv Nurse Pract; 1997 Apr; 5(4):45-9, 83. PubMed ID: 9459896
[No Abstract] [Full Text] [Related]
28. Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus.
Veloso AA; Zhu Q; Herrero-Vanrell R; Refojo MF
Invest Ophthalmol Vis Sci; 1997 Mar; 38(3):665-75. PubMed ID: 9071221
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus retinitis in persons with AIDS. Selecting therapy for a sight-threatening disease.
Balfour HH
Postgrad Med; 1995 Jan; 97(1):109-13, 117-8. PubMed ID: 7816708
[TBL] [Abstract][Full Text] [Related]
30. Support for new foscarnet indication for AIDS-related CMV retinitis is mixed.
AIDS Patient Care STDS; 1997 Oct; 11(5):377. PubMed ID: 11361828
[No Abstract] [Full Text] [Related]
31. Biodegradable scleral plugs for vitreoretinal drug delivery.
Yasukawa T; Kimura H; Tabata Y; Ogura Y
Adv Drug Deliv Rev; 2001 Oct; 52(1):25-36. PubMed ID: 11672873
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of CMV retinitis with intravitreal foscarnet].
Cochereau I; Belayachi N; Diraison C; Matheron S; Bouyer I; Hoang-Xuan T; Saimot AG; Coulaud JP
J Fr Ophtalmol; 1998 Dec; 21(10):723-6. PubMed ID: 10052044
[TBL] [Abstract][Full Text] [Related]
33. [Current status of the management of cytomegalovirus retinitis in patients with AIDS].
López-Cortés LF; Pachón-Díaz J
Enferm Infecc Microbiol Clin; 1996 Mar; 14(3):137-41. PubMed ID: 8695680
[No Abstract] [Full Text] [Related]
34. Phosphonoformate for CMV retinitis in AIDS.
Colucciello M
Am J Med; 1995 Mar; 98(3):317-8. PubMed ID: 7872354
[No Abstract] [Full Text] [Related]
35. [Intravitreal endoscopic visualization of intraocular ganciclovir devices: improved long-term treatment of CMV retinitis].
Koch FH; Gümbel HO; Hattenbach LO; Ohrloff C
Klin Monbl Augenheilkd; 1999 Feb; 214(2):107-11. PubMed ID: 10218205
[TBL] [Abstract][Full Text] [Related]
36. Cidofovir: new preparation. Of help in CMV retinitis.
Prescrire Int; 1998 Oct; 7(37):135-7. PubMed ID: 10915415
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal sustained-release ganciclovir.
Smith TJ; Pearson PA; Blandford DL; Brown JD; Goins KA; Hollins JL; Schmeisser ET; Glavinos P; Baldwin LB; Ashton P
Arch Ophthalmol; 1992 Feb; 110(2):255-8. PubMed ID: 1310588
[TBL] [Abstract][Full Text] [Related]
38. Scleral plug of biodegradable polymers for controlled drug release in the vitreous.
Hashizoe M; Ogura Y; Kimura H; Moritera T; Honda Y; Kyo M; Hyon SH; Ikada Y
Arch Ophthalmol; 1994 Oct; 112(10):1380-4. PubMed ID: 7945044
[TBL] [Abstract][Full Text] [Related]
39. Implantable biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy.
Hashizoe M; Ogura Y; Takanashi T; Kunou N; Honda Y; Ikada Y
Curr Eye Res; 1995 Jun; 14(6):473-7. PubMed ID: 7671629
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis.
Jacobson MA; Polsky B; Causey D; Davis R; Tong W; O'Donnell JJ; Kuppermann BD; Heinemann MH; Feinberg J; Lizak P
Antimicrob Agents Chemother; 1994 May; 38(5):1190-3. PubMed ID: 8067763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
